Diabetes, Vol 30, Issue 3 180-187, Copyright © 1981 by American Diabetes Association

ARTICLES

Differential time course of glucagon's effect on glycogenolysis and gluconeogenesis in the conscious dog

AD Cherrington, PE Williams, GI Shulman and WW Lacy

The evanescence of glucagon's effect on glucose production (GP) is well documented, but it is unclear (1) whether this response involves both glycogenolysis and gluconeogenesis and (2) whether the liver becomes dependent on the increased glucagon level for the maintenance of a basal supply of glucose. To answer these questions, conscious overnight-fasted dogs were given somatostatin (0.8 microgram/kg . min) plus basal intraportal replacement amounts of insulin (273 microU/kg . min) and glucagon (0.65 ng/kg . min) for 2 h, after which the rate of glucagon infusion was increased fourfold for 3 h and then returned to basal for 1.5 h. GP was determined using a primed infusion of [3-3H]glucose, and gluconeogenesis (GNG) was estimated by determining the conversion rate of alanine and lactate to glucose. An increase in the plasma glucagon level from 55 to 206 pg/ml resulted in an initial 180% increase in GP, followed by a decline such that after 3 h of hyperglucagonemia GP was increased by only 41%. Contrary to overall GP, gluconeogenesis increased progressively throughout the hyperglucagonemic period, eventually reaching a rate 3 times basal. Restoration of the basal glucagon level (63 pg/ml) caused a marked decline in GP and GNG. In fact, GP fell to a level 29% below the initial control rate and consequently the plasma glucose level fell rapidly. The data suggest that (1) the downregulation of glucagon-stimulated GP is attributable to a decline in glycogenolysis and not gluconeogenesis, and (2) following adaptation to the hormone, the liver becomes dependent on the elevated glucagon concentration for the maintenance of basal glucose production.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. Rivera, C. A. Everett-Grueter, D. S. Edgerton, T. Rodewald, D. W. Neal, E. Nishimura, M. O. Larsen, L. O. Jacobsen, K. Kristensen, C. L. Brand, et al. A Novel Glucagon Receptor Antagonist, NNC 25-0926, Blunts Hepatic Glucose Production in the Conscious Dog J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 743 - 752. [Abstract] [Full Text] [PDF]

				M. Z. Strowski, D. E. Cashen, E. T. Birzin, L. Yang, V. Singh, T. M. Jacks, K. W. Nowak, S. P. Rohrer, A. A. Patchett, R. G. Smith, et al. Antidiabetic Activity of a Highly Potent and Selective Nonpeptide Somatostatin Receptor Subtype-2 Agonist Endocrinology, October 1, 2006; 147(10): 4664 - 4673. [Abstract] [Full Text] [PDF]

				C. Everett-Grueter, D. S. Edgerton, E. P. Donahue, S. Vaughan, C. A. Chu, D. K. Sindelar, and A. D. Cherrington The effect of an acute elevation of NEFA concentrations on glucagon-stimulated hepatic glucose output Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E449 - E459. [Abstract] [Full Text] [PDF]

				P. Kishore, I. Gabriely, M.-H. Cui, J. Di Vito, S. Gajavelli, J.-H. Hwang, and H. Shamoon Role of Hepatic Glycogen Breakdown in Defective Counterregulation of Hypoglycemia in Intensively Treated Type 1 Diabetes Diabetes, March 1, 2006; 55(3): 659 - 666. [Abstract] [Full Text] [PDF]

				A.-M. Mustonen, S. Saarela, T. Pyykonen, and P. Nieminen Endocrinologic Adaptations to Wintertime Fasting in the Male American Mink (Mustela vison) Experimental Biology and Medicine, October 1, 2005; 230(9): 612 - 620. [Abstract] [Full Text] [PDF]

				R. Basu, V. Chandramouli, B. Dicke, B. Landau, and R. Rizza Obesity and Type 2 Diabetes Impair Insulin-Induced Suppression of Glycogenolysis as Well as Gluconeogenesis Diabetes, July 1, 2005; 54(7): 1942 - 1948. [Abstract] [Full Text] [PDF]

				K. F. Petersen, T. B. Price, and R. Bergeron Regulation of Net Hepatic Glycogenolysis and Gluconeogenesis during Exercise: Impact of Type 1 Diabetes J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4656 - 4664. [Abstract] [Full Text] [PDF]

				R. Basu, W. F. Schwenk, and R. A. Rizza Both fasting glucose production and disappearance are abnormal in people with "mild" and "severe" type 2 diabetes Am J Physiol Endocrinol Metab, July 1, 2004; 287(1): E55 - E62. [Abstract] [Full Text] [PDF]

				S. M. Gustavson, C. A. Chu, M. Nishizawa, B. Farmer, D. Neal, Y. Yang, S. Vaughan, E. P. Donahue, P. Flakoll, and A. D. Cherrington Glucagon's actions are modified by the combination of epinephrine and gluconeogenic precursor infusion Am J Physiol Endocrinol Metab, September 1, 2003; 285(3): E534 - E544. [Abstract] [Full Text] [PDF]

				S. M. Gustavson, C. A. Chu, M. Nishizawa, B. Farmer, D. Neal, Y. Yang, E. P. Donahue, P. Flakoll, and A. D. Cherrington Interaction of glucagon and epinephrine in the control of hepatic glucose production in the conscious dog Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E695 - E707. [Abstract] [Full Text] [PDF]

				V. M. Bonjorn, M. G. Latour, P. Belanger, and J.-M. Lavoie Influence of prior exercise and liver glycogen content on the sensitivity of the liver to glucagon J Appl Physiol, January 1, 2002; 92(1): 188 - 194. [Abstract] [Full Text] [PDF]

				K. Fosgerau, S. D. Mittelman, A. Sunehag, M. K. Dea, K. Lundgren, and R. N. Bergman Lack of hepatic "interregulation" during inhibition of glycogenolysis in a canine model Am J Physiol Endocrinol Metab, August 1, 2001; 281(2): E375 - E383. [Abstract] [Full Text] [PDF]

				D. S. Edgerton, S. Cardin, M. Emshwiller, D. Neal, V. Chandramouli, W. C. Schumann, B. R. Landau, L. Rossetti, and A. D. Cherrington Small Increases in Insulin Inhibit Hepatic Glucose Production Solely Caused by an Effect on Glycogen Metabolism Diabetes, August 1, 2001; 50(8): 1872 - 1882. [Abstract] [Full Text] [PDF]

				M. G. Bischof, M. Krssak, M. Krebs, E. Bernroider, H. Stingl, W. Waldhäusl, and M. Roden Effects of Short-Term Improvement of Insulin Treatment and Glycemia on Hepatic Glycogen Metabolism in Type 1 Diabetes Diabetes, February 1, 2001; 50(2): 392 - 398. [Abstract] [Full Text]

				P. Shah, A. Vella, A. Basu, R. Basu, W. F. Schwenk, and R. A. Rizza Lack of Suppression of Glucagon Contributes to Postprandial Hyperglycemia in Subjects with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4053 - 4059. [Abstract] [Full Text]

				P. Shah, A. Basu, R. Basu, and R. Rizza Impact of lack of suppression of glucagon on glucose tolerance in humans Am J Physiol Endocrinol Metab, August 1, 1999; 277(2): E283 - E290. [Abstract] [Full Text] [PDF]

				E. Cersosimo, P. Garlick, and J. Ferretti Insulin regulation of renal glucose metabolism in humans Am J Physiol Endocrinol Metab, January 1, 1999; 276(1): E78 - E84. [Abstract] [Full Text] [PDF]

				R. Drouin, C. Lavoie, J. Bourque, F. Ducros, D. Poisson, and J.-L. Chiasson Increased hepatic glucose production response to glucagon in trained subjects Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E23 - E28. [Abstract] [Full Text] [PDF]

				M. Shiota, P. A. Jackson, H. Bischoff, M. McCaleb, M. Scott, M. Monohan, D. W. Neal, and A. D. Cherrington Inhibition of glycogenolysis enhances gluconeogenic precursor uptake by the liver of conscious dogs Am J Physiol Endocrinol Metab, November 1, 1997; 273(5): E868 - E879. [Abstract] [Full Text] [PDF]